Adherence
GLP-1 receptor agonists are cost-effective for expanding access to obesity treatment, particularly for patients ineligible for or hesitant about surgery, and can serve as a bridge to surgery or adjunct for post-surgical regain.
If you cannot have surgery due to health risks, insurance, or wait times, GLP-1 medications are a viable, evidence-based option. They can help you lose enough weight to become a surgical candidate or manage weight after surgery. However, be prepared for lifelong use to maintain results.
GLP-1 RA can expand access to obesity treatment, particularly for patients hesitant or ineligible for surgery, and may serve as a bridge to surgery or an adjunct for postoperative weight regain.
Why this rating
Based on cohort studies and expert consensus, but long-term cost-effectiveness data is evolving.
Source
Great Debates: Undergoing the Knife versus Pill-Popping—The Comparative Efficacy and Cost-Effectiveness of Bariatric Surgery and GLP-1 Receptor Agonists in the Management of Obesity
Paul J. Brosnihan et al. · The American Surgeon · 2025
DOI 10.1177/00031348251337145
More from this paper
- Bariatric surgery (sleeve gastrectomy, gastric bypass, duodenal switch) provides superior long-term total weight loss (23.4%–40.7%) compared to GLP-1 receptor agonists (up to 25.3% with tirzepatide).Good
- Discontinuation of GLP-1 receptor agonists leads to significant weight regain (approx. two-thirds of lost weight) and loss of cardiometabolic benefits, driven partly by a surge in ghrelin.Good
Related findings · Adherence
- Regular physical activity (at least 150 minutes/week of moderate-intensity) reduces all-cause and cardiovascular mortality by 20-30% and lowers the risk of type 2 diabetes by 25-35%.Strong
- Increasing physical activity from a sedentary lifestyle to an active one in middle adulthood significantly reduces the risk of coronary events compared to remaining sedentary.Strong
- Resistance exercise is the only intervention capable of consistently restoring muscle function and strength in sarcopenia, partially overcoming age-related anabolic resistance.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →